Cyclosporine
Brand name: Restasis
Rank #26 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$684.1M
Total Cost
723,620
Total Claims
$684.1M
Total Cost
16,631
Prescribers
$945
Cost per Claim
211,455
Beneficiaries
1,158,686
30-Day Fills
$41K
Avg Cost/Provider
44
Avg Claims/Provider
Share of Medicare Part D Spending
0.25%
of total Medicare Part D spending
$684.1M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $684.1M total
🔎 Data Overview
Ranked #26 out of 500 drugs tracked by total cost. Cyclosporine represents a significant portion of Medicare drug spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Cyclosporine
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Seung-Hee Choi | Optometry | Palisades Park, NJ | 4,292 | $4.4M |
| 2 | Andrew Cho | Ophthalmology | Los Angeles, CA | 3,618 | $3.7M |
| 3 | Gee Hyun Chun | Optometry | New York, NY | 3,475 | $3.7M |
| 4 | Lisa Law | Ophthalmology | New York, NY | 3,103 | $2.8M |
| 5 | Jacqueline Dauhajre | Ophthalmology | Jackson Heights, NY | 1,769 | $2.7M |
| 6 | Benjamin Mandel | Ophthalmology | Montebello, CA | 3,880 | $2.7M |
| 7 | David Lee | Ophthalmology | Flushing, NY | 2,112 | $2.4M |
| 8 | Triet Nguyen | Ophthalmology | Westminster, CA | 2,458 | $2.3M |
| 9 | Gloria Chung | Optometry | Whitestone, NY | 1,634 | $2.1M |
| 10 | Boris Kapelnik | Optometry | Forest Hills, NY | 2,006 | $1.9M |
| 11 | Rumei Yuan | Ophthalmology | Flushing, NY | 1,329 | $1.9M |
| 12 | Maryam Yamani | Ophthalmology | Mount Vernon, NY | 1,598 | $1.8M |
| 13 | Timothy Ip | Optometry | Fresh Meadows, NY | 1,469 | $1.8M |
| 14 | Yun Kim | Ophthalmology | Buena Park, CA | 2,340 | $1.8M |
| 15 | Juan Horta-Santini | Ophthalmology | Corona, NY | 1,022 | $1.7M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology